Immunhistochemical principles

The technical test approach
Pre-analytical phase (I-II)

NQC Workshop 2016

Ole Nielsen,
Dept. of Pathology
Odense University Hospital

The total test paradigm

"Immunohistochemistry is technically complex, and no aspect of this complexity can be ignored, from the moment of collecting the specimen to issuance of the final report "
Taylor CR. Arch Pathol Lab Med 2000; 124:945

Preanalytic

Prefixation
Fixative
Fixation
Postfixation
Processing
Dehydration and clearing
Paraffin impregnation
Paraffin sectioning
Storage



Analytic

Epitope retrieval
Blocking
Primary Antibody
Dilutent
Detection system
Chromogen
Counter stain
Mounting

Interpretive

Design of controls
Positive controls
Negative controls
Interpretation
Critical Stain Indicator

indivumed

NordiQC

Ca. 60 „Targeted Therapies“ are Approved and >800 Compounds are in Clinical Trial

(Status 2012/01)

Some require IHC-based Companion Diagnostics!



Prof. Dr. Hartmut Juhl
CEO of Indivumed GmbH and Inostics GmbH
Adjunct Professor, Georgetown University and Hamburg University
www.indivumed.com
juhl@indivumed.com

Thyroid carcinoma: Biology or artefact?

TTF-1, SPT24

CD138, B-A38

Thyroid carcinoma: Biology or artefact?



TTF-1, SPT24

CD138, B-A38



PAX-8, ZR-1

PAX-8, pAb (CM363A)

A tissue quality index: an intrinsic control for measurement of effects of preanalytical variables on FFPE tissue

Veronique M Neumeister[1], Fabio Parisi[1], Allison M England[1], Summar Siddiqui[1], Valsamo Anagnostou[1], Elizabeth Zarrella[1], Maria Vassilakopolou[1], Yalai Bai[1], Sasha Saylor[1], Anna Sapino[2], Yuval Kluger[1,2], David G Hicks[3], Gianni Bussolati[2], Stephanie Kwei[4] and David L Rimm[1]

Laboratory Investigation (2014) 94, 467–474

If we cannot control pre-analytical variables can we quantify the damage or tissue degradation caused by them?

Effects of Preanalytical Variables on the Detection of Proteins by Immunohistochemistry in Formalin-Fixed, Paraffin-Embedded Tissue

Kelly B. Engel, PhD; Helen M. Moore, PhD

Arch Pathol Lab Med—Vol 135, May 2011

Table 1. Potential Sources of Preanalytic Variation During Specimen Fixation and Processing

- Prefixation
  - Duration and delay of temperature
  - Specimen size
  - Specimen manipulation (pathology ink)
- Fixative
  - Formula
  - Concentration
  - pH
  - Age of reagent
  - Preparation source
- Fixation
  - Tissue to fixative volume ratio
  - Method (immersion, injection, and sonication or microwave acceleration)
  - Conditions of primary and secondary fixation
    - Movement
    - Light exposure
    - Primary container
    - No. and position of cofixed specimens
- Postfixation
  - Washing conditions and duration
  - Storage reagent and duration
- Processing
  - Type of processor, frequency of servicing and reagent replacement
  - Tissue to reagent volume ratio
  - No. and position of coprocessed specimens
- Dehydration and clearing
  - Reagent
  - Temperature
  - No. of changes
  - Duration (total and change-specific)
- Paraffin impregnation
  - Type and melting point of wax
  - No. of changes
  - Duration (total and change-specific)
  - Method (immersion and sonication or microwave acceleration)
- Paraffin sectioning
  - Type of blade and frequency of replacement
  - Frequency of servicing and wax replacement
  - Temperature of block during sectioning
  - Slide pretreatment
  - Water bath conditions, if used
  - Chemical adhesives, if used
  - Temperature and duration of slide drying
- Storage
  - Temperature and duration of paraffin block storage
  - Temperature, duration, and manipulation of slide-mounted tissue sections

Decalcification:
Type, Time, Temperature

Prefixation

- Surgical procedures
- Fixation delay / ischemia (time and temperature)
- Specimen size
- Specimen manipulation (pathology ink)

Surgical procedures - Impact on IHC

RCC



CK7/8, CAM5.2

CK8, EP17



CD10, 56C6

Surgical procedures - Impact on IHC

RCC

Electrosurgery (Heat denaturation)



CK7/8, CAM5.2



CK8, EP17



CD10, 56C6

“Electrosurgery” (Heat) RCC



Pencil marking of small biopsies



HE (Kidney)



PAS (Kidney)

Pencil marking of small biopsies



KIM-1 (Kidney with marking)



KIM-1 (Kidney without marking)

Prefixation

- Surgical procedures
- Fixation delay / ischemia (time and temperature)
- Specimen size
- Specimen manipulation (pathology ink)

Seminoma: Biology or Artefact?

PMS2, EPR3947



MSH6, EP49

Seminoma: Biology or Artefact?

NordiQC

Delay of fixation?
Fixation procedure?

PMS2, EPR3947

Effect of Delayed Formalin Fixation on Estrogen and Progesterone Receptors in Breast Cancer

A Study of Three Different Clones

Am J Clin Pathol 2010;134:813-819

Jingxin Qiu, MD, PhD,[1] Swati Kulkarni, MD,[2] Rameela Chandrasekhar,[3] Mark Rees, PhD,[4,6] Kathryn Hyde,[5] Gregory Wilding, PhD,[3] Dongfeng Tan, MD,[6] and Thaer Khoury, MD[1]

Effect of Delayed Formalin Fixation on Estrogen and Progesterone Receptors in Breast Cancer

A Study of Three Different Clones

Am J Clin Pathol 2010;134:813-819

Jingxin Qiu, MD, PhD,[1] Swati Kulkarni, MD,[2] Rameela Chandrasekhar,[3] Mark Rees, PhD,[4,6] Kathryn Hyde,[5] Gregory Wilding, PhD,[3] Dongfeng Tan, MD,[6] and Thaer Khoury, MD[1]



Image 1 (Case 9) Estrogen receptor expression by clones 1D5 (DAKO), 6F11 (Leica), and SP1 (Ventana) at different delayed formalin fixation times (0 minutes, 4 and 8 hours, and overnight). Note the decreased number/percentage of positive cells and the intensity of the stain with increased time of delayed fixation.



Figure 1 Mean Q score decline for estrogen receptor by clones 1D5 (DAKO), 6F11 (Leica), and SP1 (Ventana) in relation to time of fixation.

Effect of Delayed Formalin Fixation on Estrogen and Progesterone Receptors in Breast Cancer

A Study of Three Different Clones

Am J Clin Pathol 2010;134:813-819

Jingxin Qiu, MD, PhD,[1] Swati Kulkarni, MD,[2] Rameela Chandrasekhar,[3] Mark Rees, PhD,[4,6] Kathryn Hyde,[5] Gregory Wilding, PhD,[3] Dongfeng Tan, MD,[6] and Thaer Khoury, MD[1]

Based on our findings, it appears that regardless of the antibody clones evaluated, delayed formalin fixation has a negative effect on hormone receptors.



Image 3 (Case 8) Progesterone receptor expression by clones PgR636 (DAKO), 16 (Leica), and 1E (Ventana) at different delayed formalin fixation times (0 minutes, 1 and 8 hours, and overnight).



Figure 2 Mean Q score decline for progesterone receptor (clones PgR636, 16 and 1E2) in relation to time of fixation. Values were not statistically significant by the Page L test.

The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma

Isil Z Yildiz-Aktas, David J Dabbs and Rohit Bhargava

MODERN PATHOLOGY (2012) 25, 1098–1105



"Non-refrigerated samples are affected more by prolonged cold ischemic time than refrigerated samples. Cold ischemic time period of as short as one-half hour may occasionally impact the immunohistochemical (IHC) staining for progesterone receptor. Significant reduction in IHC staining for hormone receptors, and HER2, however, generally does not result until 4 h for refrigerated samples and 2 h for non-refrigerated samples. The ASCO/CAP guideline of cold ischemic time period of 1 h is a prudent guideline to follow".

Stability of Phosphoprotein as a Biological Marker of Tumor Signaling

Amanda F. Baker,[1] Tomislav Dragovich,[1] Nathan T. Ihle,[1] Ryan Williams,[1]
Cecilia Fenoglio-Preiser,[2] and Garth Powis[1]

Clin Cancer Res 2005;11(12) June 15, 2005



Fig. 1. Phospho-AKT in human gastroesophageal tumors and HT-29 colon cancer xenografts measured by immunohistochemical staining. Staining used phospho-Ser^{473}-Akt antibody. *A*, patient tumor samples. 1 and 2 are two surgically resected specimens and 3 and 4 are two biopsy specimens. *B*, HT-29 human tumor xenografts were excised from *scid* mice and kept at room temperature for the times shown. Small pieces were fixed in 5% formalin for immunohistochemistry. Each section also includes in the upper right-hand quadrant an on-slide control of HT-29 colon cancer cells stained for phospho-Ser^{473}-Akt.



Conclusions: Caution should be used when using phosphoprotein levels in human tumor specimens to measure intrinsic signaling activity or drug effects because of the potential for rapid dephosphorylation. Rapid processing of biopsies is essential and postoperative surgical samples may be of limited value because of the time to fixation.

Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables

Yalai Bai[1], Juliana Tolles[2], Huan Cheng[1], Summar Siddiqui[1], Arun Gopinath[1], Eirini Pectasides[1], Robert L Camp[1], David L Rimm[1] and Annette M Molinaro[2]

Laboratory Investigation (2011) 91, 1253–1261



Figure 2 Comparison of biomarker staining images between biopsies *vs* tumor resections on whole tissue section slides. Representative immunofluorescence staining of pAKT (red) in CNB (**a**) and tumor resection (**b**), AKT (red) in CNB (**c**) and tumor resection (**d**), ER (red) in CNB (**e**) and tumor resection (**f**), and GAPDH (red) in biopsy (**g**) and tumor resection (**h**) was illustrated. Each corresponding cytokeratin staining is shown as inset (green). Photographs are shown at magnification of $\times 20$.

Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables

Yalai Bai[1], Juliana Tolles[2], Huan Cheng[1], Summar Siddiqui[1], Arun Gopinath[1], Eirini Pectasides[1], Robert L Camp[1], David L Rimm[1] and Annette M Molinaro[2]

Laboratory Investigation (2011) 91, 1253–1261



Figure 1 Differences in biomarker expression in core needle biopsies *vs* tumor resections. Twenty core needle biopsies and matched tumor resections were arrayed in TMA with two-fold redundancy. In all, 1.5 mm core from each tumor block was arrayed in a recipient block. The TMA was immunohistochemically stained with ER, p53, Ki67, pERK, pAKT and pTyr and the results were quantified using AQUA. Scores represent the average of two cores. Specimens that showed decreased staining in the resection relative to biopsy are shown in green; those with higher resection levels are shown in red.

Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables

Yalai Bai[1], Juliana Tolles[2], Huan Cheng[1], Summar Siddiqui[1], Arun Gopinath[1], Eirini Pectasides[1], Robert L Camp[1], David L Rimm[1] and Annette M Molinaro[2]

Laboratory Investigation (2011) 91, 1253–1261

- Detection levels for all phospho-epitopes were significantly decreased in tumor resections compared with biopsies while no significant change was seen in the corresponding total proteins.
- ER and cytokeratin showed significant loss of antigenicity.
- This data suggest that measurement of phospho-protein antigenicity in formalin-fixed tissue by immunological methods is dramatically affected by pre-analytic variables.
- This study suggests that core needle biopsies are more accurate for assessment of tissue biomarkers.

Delay of fixation

Phosphoprotein pMAPK IHC of Colon Cancer :
Gain of Biomarker Signal with Time to Fixation

10 min

20 min

60 min



Hartmut Juhl, Indivumed GmbH, BRN

Vacuum Sealing and Cooling as Methods to Preserve Surgical Specimens

Thomas Kristensen, PhD, Birte Engvad* Torsten Pless, MD,†*
Steen Walter, MD, DMSc ak, MD**

Appl Immunohistochem Mol Morphol. 2011 Oct;19(

Liver, kid nd breast

TABLE 1. Antibody Clones and Dilutions and Epitope Retrieval Procedures

Antibody	Clone	Source	Dilution	Retrieval
CD4	SP35	Ventana	RTU	CC1mild
CD8	C8/144B	Ventana	RTU	CC1std
CD10	56C6	Leica	1:10	CC1std
CD13	38C12	Leica	1:25	CC1mild
CD14	7	Leica	1:25	CC1std
CD34	QBEnd/10	Ventana	RTU	CC1mild
CD68	PG-M1	Dako	1:50	CC1std
CD138	B-A38	Ventana	RTU	CC1mild
CD138	BC/B-B4	Biocare	1:500	CC1mild
CDX2	EPR2764Y	Ventana	RTU	CC1std
CK7+8	CAM 5.2	BD	1:10	Protease 1: 8min
CK7	SP52	Ventana	RTU	CC1std
CK7	OV-TL12/30	Ventana	RTU	CC1std
CK18	DC10	Dako	1:25	CC1std
CK20	SP33	Ventana	RTU	CC1std
E-Cad	ECH-6	Ventana	RTU	CC1std
E-Cad	HECD-1	Abcam	1:50	CC1std
ER	SP1	Ventana	RTU	CC1std
HEPA	OCH1E5	Ventana	RTU	CC1mild
HLA-DR	CR3/43	Dako	1:200	CC1mild
Ki67	30-9	Ventana	RTU	CC1std
Lamins A/C	EPR4100	Epitomics	1:4000	CC1std
PgR	1E2	Ventana	RTU	CC1mild
Villin	CWWB1	Ventana	RTU	CC1std

FIGURE 1. A t samples were included for each of the 5 organ types included in the study. The nental time = 0 hour. Experimental samples were collected after 1, 2, 4, 8, 20, 44, n fixed for approximately 48 hours before further processing and paraffin embed chemical and morphologic endpoints. Samples labeled "R" were snap frozen ano n and analysis of RNA integrity. Samples labeled "R" were not analyzed with r ssue morphology or epitope T indicates room temperature.

Vacuum Sealing and Cooling as Methods to Preserve Surgical Specimens

Thomas Kristensen, PhD, Birte Engvad, MD,* Ole Nielsen, MT,* Torsten Pless, MD,† Steen Walter, MD, DMSc, FEBU,‡ and Martin Bak, MD**

Appl Immunohistochem Mol Morphol. 2011 Oct;19(5):460-9.

Liver, kidney, spleen, colon and breast

TABLE 1. Antibody Clones and Dilutions and Epitope Retrieval Procedures

Antibody	Clone	Source	Dilution	Retrieval
CD4	SP35	Ventana	RTU	CC1mild
CD8	C8/144B	Ventana	RTU	CC1std
CD10	56C6	Leica	1:10	CC1std
CD13	38C12	Leica	1:25	CC1mild
CD14	7	Leica	1:25	CC1std
CD34	QBEnd/10	Ventana	RTU	CC1mild
CD68	PG-M1	Dako	1:50	CC1std
CD138	B-A38	Ventana	RTU	CC1mild
CD138	BC/B-B4	Biocare	1:500	CC1mild
CDX2	EPR2764Y	Ventana	RTU	CC1std
CK7+8	CAM 5.2	BD	1:10	Protease 1: 8min
CK7	SP52	Ventana	RTU	CC1std
CK7	OV-TL12/30	Ventana	RTU	CC1std
CK18	DC10	Dako	1:25	CC1std
CK20	SP33	Ventana	RTU	CC1std
E-Cad	ECH-6	Ventana	RTU	CC1std
E-Cad	HECD-1	Abcam	1:50	CC1std
ER	SP1	Ventana	RTU	CC1std
HEPA	OCH1E5	Ventana	RTU	CC1mild
HLA-DR	CR3/43	Dako	1:200	CC1mild
Ki67	30-9	Ventana	RTU	CC1std
Lamins A/C	EPR4100	Epitomics	1:4000	CC1std
PgR	1E2	Ventana	RTU	CC1mild
Villin	CWWB1	Ventana	RTU	CC1std





FIGURE 1. A total of 70 experimental samples and 6 reference samples were included for each of the 5 organ types included in the study. The 6 reference samples were collected at the experimental time = 0 hour. Experimental samples were collected after 1, 2, 4, 8, 20, 44, or 92 hours. Samples labeled "IM" were formalin fixed for approximately 48 hours before further processing and paraffin embedding and analyzed with respect to immunohistochemical and morphologic endpoints. Samples labeled "R" were snap frozen and stored at −80°C until subsequent RNA extraction and analysis of RNA integrity. Samples labeled "R" were not analyzed with respect to tissue morphology or epitope integrity. RT indicates room temperature.

Results - Morphology and IHC



FIGURE 4. A, Morphologic integrity scores as a function of time in the 4 treatment groups: room temperature with vacuum ((—●—)), room temperature without vacuum ((—■—)), 4°C with vacuum ((- - ● - -)), and 4°C without vacuum ((- - ■ - -)). Each data point represents the mean of the score values in the 5 tissues. B, IHC staining quality scores as a function of time in the 4 treatment groups. Each data point represents the mean of all score values from all antibodies in all 5 tissues. Quality score value 4 corresponds to optimal, 3 corresponds to good, 2 corresponds to borderline, and 1 corresponds to poor morphologic integrity or IHC staining quality. Experimental time = 0 hour is depicted as 0.1 hour in both panels. IHC indicates immunohistochemical.

E-Cadherin, HECD1 - Kidney



Ref. No delay



92hrs at 4°C/no vac



92hrs at 4°C/vac

E-Cadherin, HECD1 - Kidney



Ref. No delay



92hrs at 4°C/no vac



92hrs at RT/vac

CD138, B-A38 - Kidney



Ref. No delay



8hrs at 4°C/no vac



8hrs at 4°C/vac

CD138, B-A38 - Kidney







"Despite the differences in the rate of loss of epitope integrity in this study, the results from the multiple IHC analysis consistently supported the overall conclusion that cooling at 4°C preserves tissue in contrast to vacuum sealing which has no tissue-preserving effect".

Ref. No delay

8hrs at 4°C/no vac

92hrs at 4°C/vac

Fixation delay

Preanalytic variable	Published Guidelines and Recommendations ASCO/CAP | CLSI	Literature-Based Recommendations
Fixation delay	Less than 1 hr	Less than 12 hrs 4°C is better than RT

Engel KB, Moore HM. Arch Pathol Lab Med. 2011;135:537-543

I/LA28-A2
Vol. 31 No. 4
Replaces MM04-A
Vol. 19 No. 26

Quality Assurance for Design Control and Implementation of Immunohistochemistry Assays; Approved Guideline—Second Edition

Stephen M. Hewitt, MD, PhD
Max Robinowitz, MD
Steven A. Bogen, MD, PhD
Allen M. Gown, MD
Krishan L. Kalra, PhD
Christopher N. Otis, MD
Betsy Spaulding
Clive R. Taylor, MD, DPhil

+ A long list of experts and advisors

This document provides guidelines for the development of validated diagnostic, prognostic, and predictive immunohistochemical assays.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

CLINICAL AND LABORATORY STANDARDS INSTITUTE®

(CLSI)

Seminoma: Biology or Artefact?

Fixation procedure?



PMS2, EPR3947

Fixation procedure

- Fixative
  - Formula
  - Concentation
  - pH
- Fixation
  - Tissue to fixative ratio
  - Method (Immersion, MWO, sonication, movement etc)
  - Time
  - Temperatur
- Postfixation
  - Washing conditions and duration
  - Storage reagent and duration

Formaldehyde fixation



Phase 1	Penetration	Very fast
Phase 2	Binding	Very slow
Phase 3	Cross-linking	Slow

Formaldehyde obey the diffusion laws, that is, the depth penetrated is proportional to the square root of time.

Penetration rate can be determind using the equation:

$$d = K\sqrt{t}$$

d = Distance penetrated in mm
K = Medawar's coefficient of diffusibility
t = Time in hours

Medawar's K = 5,5
Alternative:
Baker's K = 3,6
Hewletts K = 2,0

Formaldehyde fixation

Region Syddanmark
OUH
Afd. f.
Klinisk
Patologi
O. Nielsen



Fixation:
NBF 24 hrs



Penetration rate can be determind using the equation: $d = K\sqrt{t}$

Medawar's K = **5,5**
Baker's K = **3,6**

Hewletts K = **2,0**:

1 second d = 0.033 mm (124 mm/hr)
1 minute d = 0.26 mm (15.5 mm/hr)
4 minutes d = 0.52 mm (7.8 mm/hr)
16 minutes d = 1.04 mm (3.9 mm/hr)
1 hour d = 2.0 mm (2.0 mm/hr)
4 hours d = 4.0 mm (averages to 1.0mm/hr),
8 hours d = 5.66 mm (averages to 0.7mm/hr),
16 hours d = 8.0 mm (averages to 0.5mm/hr),
24 hours d = 9.8 mm (averages to 0.41mm/hr),
96 hours d = 19.6 mm (averages to 0.2mm/hr).

Formaldehyde fixation



Phase 1	Penetration	Very fast
Phase 2	Binding	Very slow
Phase 3	Cross-linking	Slow

Phase 2



Phase 3

Kinetic Studies of Formaldehyde Binding in Tissue

Biotechnique and Histochemistry. 1994; **69**, 177-179

Kerstin G. Helander
Laboratory of Membrane Biology, Center for Ulcer Research and Education, University of California, Los Angeles, California 90073



4x4x4 mm liver tissue



100% formaldehyde binding after app. 25 hrs



Kinetic Studies of Formaldehyde Binding in Tissue

Kerstin G. Helander

ucation, University of California,

Biotechnique and Histochemistry. 1994; **69**, 177-179

"There is a misconception that smaller biopsy samples will fix more quickly than larger resection specimens and therefore require less time in formalin."

David G. Hicks





100% formaldehyde binding after app. 25 hrs



Kinetic Studies of Formaldehyde Binding in Tissue

Kerstin G. Helander
Laboratory of Membrane Biology, Center for Ulcer Research and Education, University of California, Los Angeles, California 90073

Biotechnique and Histochemistry. 1994; **69**, 177-179

Formaldehyde binding is reversible:

4x4x4 mm liver tissue





Rinsing with dH_2O

Seminoma





Edge



Center

PMS2, EPR3947 and fixatives

Clone EPR3947 can not be used on alcohol-fixed tissue



Bouin 24 hrs

Zamboni 24 hrs

Clarke 24 hrs

Carnoy 24 hrs

Methacarn 24 hrs

Form/Zn 24 hrs

Ethanol 24 hrs

NBF168 hrs

NBF 48 hrs

NBF 24 hrs

NBF 6 hrs

Fixation of cells
anti-TdT (poly) on MOLT4 cells

Acetone 5’



Methanol 5’



Ethanol 5’



Acetone/Methanol 5’



NBF 5’



NBF 5’ + Triton X100 wash



Minimum Formalin Fixation Time for Consistent Estrogen Receptor Immunohistochemical Staining of Invasive Breast Carcinoma

Neal S. Goldstein, MD, Monica Ferkowicz, MT(ASCP), PathA(AAPA), Eva Odish, HTL(IHQ), Anju Mani, MD, and Farnaz Hastah, MD

Am J Clin Pathol 2003;120:86-92



Image 1 Fixation, 3 h; antigen retrieval, 40 min.



Image 2 Fixation, 6 h; antigen retrieval, 40 min.



Image 3 Fixation, 8 h; antigen retrieval, 40 min.

"The minimum formalin fixation time for reliable immunohistochemical ER results is 6 to 8 hours in our laboratory, regardless of the type or size of specimen".

(*Am J Surg Pathol* 2011;35:545–552)

The Effect of Prolonged Fixation on the Immunohistochemical Evaluation of Estrogen Receptor, Progesterone Receptor, and HER2 Expression in Invasive Breast Cancer: A Prospective Study

Leung Chu Tong, BA, MD, Nahid Nelson, BSc, PhD,† Jim Tsourigiannis, BSc, M*
and Anna Marie Mulligan, MB, MSc, FRCPath†*

TABLE 1. Antibodies and Conditions of Use

	Clone	Source	Antigen Retrieval Time
ER	SP1 (Monoclonal)	Ventana	30 min
PR	1E2 (Monoclonal)	Ventana	60 min
HER2	A0485 (Polyclonal)	DAKO	30 min

Fixation i 4% NBF for 13 hours versus 79 hours

Concordance between short fixation and long fixation:

99 % Concordance for ER

95 % Concordance for PR

98 % Concordance for HER2



FIGURE 1. Distribution of (A) Allred scores for ER staining ($P = 1.0$), (B) Allred scores for PR staining ($P = 0.8625$), and (C) HER2 scores ($P = 1.0$) in the SF and PF groups.

Alternatives to 4% NBF...

Name	Contains...	Company
F-solv	Denat. EtOH / Aldehyde derivate / Stabiliser	Yvsolab
UPM	Ethanol / Methanol / 2-Propanol / Formaldehyde	Copan
GreenFix	Ethandial / Ethanol	Diapath
CyMol	Ethanol / Methanol / 2-Propanol	Copan
RCL-2	Ethanol / Acetic acid / Complex carbohydrates	Alphelys
FineFix	Ethanol / Glycerol / PVA / Simple carbohydrates	Milestone
Formaldehyde-EtOH	Formaldehyde / Ethanol / Buffer	BBC Biochemical
Zn-Formalin	Formaldehyde / Methanol / Zn-sulfate	Richard-Allen
Prefer	Glyoxal / Ethanol	Anatech
Davidson's AFA	Formaldehyde / Ethanol / Ac[illegible] acid	Electron Micr. Sci.
Molecular Fixativ	Methanol / Polyethyleng[illegible]	Sakura
Pen-Fix	Formaldehyde / Ethanol [illegible]	Richard-Allen
Histochoice	Glyoxal / Zn-sulfate / [illegible]	[illegible]meresco-Inc.
O-Fix	Formaldehyd / Etha[illegible]	SurgiPath
GTF	Glyoxal / Ethanol	StatLab Medical
PAXgene Tissue-fix	Alcohols / Acid / A soluble organic compound	Qiagen- PreAnalytix

PAXgene Tissue
New Tissue Fixation/Stabilization Technology

- Development began in 2007:
  - >1,500 compounds and combinations screened
  - >8,000 tissue samples tested to date
- Technology requirements
  - Histomorphology must be equivalent to FFPE tissue
  - RNA, DNA, miRNA must be preserved and of high quality
- Two-reagent system finalized in 2009
  - Fixation and stabilization reagents, both formalin-free
- First collection device
  - Container with two chamber one closure
- Under evaluation within SPIDIA

Consortium	7 public research organizations, 8 companies, 1 standards organization (CEN)
Coordinator	QIAGEN GmbH

PreAnalytiX
A QIAGEN / BD Company

Summary
PAXgene Tissue …

- … is a standardized system for tissue fixation, stabilization and biomolecule purification.
- … preserves histomorphology and biomolecules.
- … works without crosslinking and chemical modification.
- … treated tissue can be stored within the stabilization reagent, or after processing.
- … results in comparable morphology but superior molecular results
- … requires protocol adaptations for immunhistochemistry staining

PAXgene Tissue enables multimodal analysis of biomolecules from the same sample, which is used for morphological analysis

Immunhistochemistry
Ki67 - Optimization of Epitope Retrieval

- Human tonsil
- Ki-67, clone MIB-1, Labelled streptavidin-biotin (LSAB) assay





PreAnalytiX
A QIAGEN / BD Company

Immunhistochemistry
Estrogen and Progesteron Receptor

- Human breast cancer cases (Cureline)
- Labelled streptavidin-biotin (LSAB) assays
- 10 - 20 min 98°C, Tris/EDTA buffer pH 9



www.preanalytix.com/.../tissue-atlas

PreAnalytiX
A QIAGEN / BD Company

Will PAXgene substitute formalin? A morphological and molecular comparative study using a new fixative system

Benedetta Belloni,[1] Chiara Lambertini,[2] Paolo Nuciforo,[2] Jay Phillips,[3] Eric Bruening,[3] Stephane Wong,[3] Reinhard Dummer[1]

J Clin Pathol 2013;**66**:124–135.

Morphology was well preserved in PAXPE samples. However, 5 out of 11 immunohistochemical markers showed significantly lower overall staining and staining intensity with PAXPE tissues in comparison with formalin-fixed, paraffin-embedded (FFPE).



Take home messages

- In PAXPE samples, morphology is well preserved but immunohistochemistry requires re-evaluation of markers and staining procedures.
- PAXPE samples provide greater template integrity of mRNA amplicons than formalin-fixed, paraffin-embedded samples.
- DNA fragmentation seems to be lower in PAXPE samples compared with formalin-fixed, paraffin-embedded samples.
- The authors would not suggest substituting formalin fixation with PAXgene fixation in a routine pathology laboratory.

Choice of Fixative Is Crucial to Successful Immunohistochemical Detection of Phosphoproteins in Paraffin-embedded Tumor Tissues

(J Histochem Cytochem 57:257–264, 2009)

Janine A. Burns, Yuan Li, Carol A. Cheney, Yangsi Ou, Laura L. Franlin-Pfeifer, Nelly Kuklin, and Zhi-Qiang Zhang

Department of Biologics Research, Merck Research Laboratories, West Point, Pennsylvania



Figure 2 IHC staining of phosphoproteins in xenograft and human clinical tumor tissues. (**A**) SKOV-3 xenograft tumor tissues fixed in Streck's tissue fixative (STF), 10% formalin, and 4% paraformaldehyde (PFA) were stained with anti-pMet antibody. (**B**) Human lung tumor tissue fixed in 10% formalin and STF were stained with anti-pHER4 antibody. Bar = 50 μm.

Streck's tissue fixative (STF)

"We found that STF significantly enhanced the staining intensity of phosphoproteins compared with 10% formalin or 4% PFA. Our results indicate that the choice of fixative could significantly affect the usability of clinical tissue samples for evaluating phosphoprotein by IHC".

OPEN ACCESS Freely available online

PLOS ONE

Rapid Two-Temperature Formalin Fixation

David Chafin[1☯], Abbey Theiss[1☯], Esteban Roberts[1], Grace Borlee[2¤], Michael Otter[1], Geoffrey S. Baird[2,3*]

1 Ventana Medical Systems, Inc., Tucson, Arizona, United States of America, 2 Department of Laboratory Medicine, University of Washington, Seattle, Washington, United States of America, 3 Department of Pathology, University of Washington, Seattle, Washington, United States of America

bcl-2 IHC after different fixation conditions

Control	No Pre-Soak				2 Hr Pre-Soak (4°C)			
RT 10% NBF	35° 10% NBF	40° 10% NBF	45° 10% NBF	50° 10% NBF	35° 10% NBF	40° 10% NBF	45° 10% NBF	50° 10% NBF
0 hr	0.5 hr	0.5 hr	0.5 hr	0.5 hr	0.5 hr	0.5 hr	0.5 hr	0.5 hr
2 hr	1 hr	1 hr	1 hr	1 hr	1 hr	1 hr	1 hr	1 hr
4 hr	2 hr	2 hr	2 hr	2 hr	2 hr	2 hr	2 hr	2 hr
8 hr	4 hr	4 hr	4 hr	4 hr	4 hr	4 hr	4 hr	4 hr
24 hr	6 hr	6 hr	6 hr	6 hr	6 hr	6 hr	6 hr	6 hr





4% NBF versus FineFix



Breast - ER, clone 1D5



Liver - Hepartocyt Ag, clone OCHIE5

"With existing IHC-protocols 35% (9 of 26) of the antibodies gave poor or borderline reactions on tissues fixed in FineFix"

(Unpublished data)

Vimentin (V9) and various fixatives

No retrieval



Vimentin (V9) and various fixatives



Fixation

Preanalytic variable	Published Guidelines and Recommendations ASCO/CAP | CLSI	Literature-Based Recommendations
Fixative formula	4% NBF #	4% NBF
Time in fixative	24 hrs*	24 hrs
Tissue to fixative ratio	1:10	1:1 to 1:20

Engel KB, Moore HM. Arch Pathol Lab Med. 2011;135:537–543


Arch Pathol Lab Med—Vol 131, January 2007

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer

*6-48 hrs


Appl Immunohistochem Mol Morphol • Volume 16, Number 6, December 2008

Consensus Recommendations on Estrogen Receptor Testing in Breast Cancer By Immunohistochemistry

*8-72 hrs 4% phosphate buffered formaldehyde, pH 7,0 - 7,4

4% NBF = 4% neutral buffet formaldehyde = 10% neutral buffet formalin

Decalcification

- Type
  - Strong acid (e.g. HCl)
  - Weak organic acid (e.g. formic acid)
  - Chelating agents (e.g. EDTA)
- Time, Temperature
- Time in fixative before decalcification

Call for a European programme in external quality assurance for bone marrow immunohistochemistry; report of a European Bone Marrow Working Group pilot study

J Clin Pathol 2009;**62**:547–551. doi:10.1136/jcp.2008.063446

E E Torlakovic,[1] K Naresh,[2] M Kremer,[3] J van der Walt,[4] E Hyjek,[5] A Porwit[6]

Take-home messages

- Immunohistochemistry tests are commonly if not regularly used in bone marrow trephine biopsies (BMTB) obtained for both primary and secondary bone marrow diseases, with or without morphological evidence of disease.
- Proficiency testing for BMTB immunohistochemistry (IHC) by extralaboratory quality assurance (EQA) programmes is not possible if the number of methods for tissue processing is not markedly reduced.
- The survey determined that almost all participants believed that their results were either "good" or "optimal" (90%) and that their daily QC/QA programmes were either "good" or "optimal" (93%); however, only 21% of laboratories were found to produce no poor results. This discrepancy is particularly important because it was shown with most commonly used IHC tests.
- The European Bone Marrow Working Group IHC Group is calling for a reduction in the number of methods used for BMTB processing and establishment of a unified EQA programme for BMTB IHC for all European countries.

Table 1 Tissue processing

Fixative	**n (28)**
10% NBF	15
5% NBF	1
B5	5
AZF	4
Schäffer's fixative	2
Burckhard fixative	1
F–G mixture	1
SUSA	1
Fixation time	**2 to >24 hours**
Exact and uniform	5
Variable	23
Decalcification	**n (28)**
None	2
EDTA	16
RDO (Rapid Decalcifier)	1
SUSA (acid)	1
10% nitric acid	1
Stieve solution*	1
Gooding and Stewart's†	4
Zenker/glacial acetic acid solution	1
Osteosoft	1
Decalcification time	**45 minutes to 3 days‡**
Exact and uniform timing	15
Variable	13

*Mercuric chloride/formaldehyde/acetic acid; †10% formic acid and 5% formaldehyde; ‡mostly depending of decalcifying reagent.
AZF, acetic acid–zinc–formalin; F–G mixture, formaldehyde–glutaraldehyde mixture; NBF, neutral buffered formalin; SUSA, sublimate mercury II chloride.

IHC and decalcification

- ✓ Decalc™ (HCl-based)
- ✓ Buffet formic acid (4M formic acid + 0.5M Na-formiat)
- ✓ 10% EDTA, pH 7

IHC and decalcification (2007)

24 hrs 4% NBF fixation prior to decalcification. 124 different antibodies on TMA's

Method \ Intensity	0/+	++	+++	++++
EDTA, 10% pH7	0	0	119	5
Formic acid (BFA)	2	13	103	6
Decalc™ (HCl)	101	21	2	0

Reference/No decalcification: ++++

Buffet formic acid (BFA): (4M formic acid + 0.5M Na-formiat)

IHC and decalcification (2007)

Antibody	Clone	Ref	Decalc	Formic	EDTA
Elastase, neutrophil , NP57	NP57	+++	0	0	+++
CD105, SN6h	SN6h	+++	0	+	+++
Bcl-2, 124 -Oncoprotein	124	+++	0	++	+++
Bcl-6, PG-B6p	PG-B6p	+++	0	++	+++
CD40, 11E9	1,1E+10	+++	0	++	+++
Factor XIII-a, poly		+++	+	++	+++
Oct-1, 12F11	12F11	+++	0	++	+++
Oct-2 (C20), poly		+++	0	++	+++
MUM1, MUM1p -Multiple Myeloma	MUM1p	+++	+	++	+++
Bob 1, TG14	TG14	+++	0	++	+++
CD4, 4B12	4B12	+++	0	++	+++
CD43, MT1	MT1	+++	0	++	+++
TCAR, BF1 -T-Cell Antigen	ßF1	+++	0	++	+++
CD16, 2H7- Fc Gamma Receptor	2H7	+++	0	++	+++
CD52, HI186	HI186	+++	0	++	+++

Decalcification and Elastase, neutrophilic, NP57









Decalcification and CD105, SN6h



No decalcification



Formic acid 16hrs



EDTA 96hrs

Decalcification and CD105, 4G11



No decalcification



Formic acid 16hrs



EDTA 96hrs

IHC and decalcification (2014)

24 hrs 4% NBF fixation prior to decalcification. 193 different antibodies on TMA's

Method \ Intensity	0/+	++	++(+)	+++	++++
EDTA, 10% pH7	0	0	5	185	3
Formic acid (BFA)	1	15	8	163	6
DecalcTM (HCl)	159	23	1	8	2

Reference/No decalcification: ++++

Buffet formic acid (BFA): (4M formic acid + 0.5M Na-formiat)

IHC and decalcification (2014)

Antibody	Reference	DECAL	Formic	EDTA
CD303, 124B3.13	+++	+	+	+++
Makrofag, MAC 387	+++	0	++	++(+)
Bcl-2, 124 *	+++	0	++	+++
TCAR, BF1 *	+++	0	++	+++
Galectin-3, 9C4	+++	0	++	+++
Caveolin-1, 4D6	+++	0	++	+++
CD279, NAT105	+++	0	++	+++
Inhibin Alpha, R1	+++	0	++	+++
Bcl-2, E17	+++	0	++	+++
FOXP1, EPR4113	+++	0	++	+++
pHH3, E173	+++	0	++	+++
CD1a, EP3622	+++	0	++	+++
CD19, SP110	+++	0	++	+++
CD103, EPR4166(2)	+++	0	++	+++
CD123, 6H6	+++	0	++	++++
Neuroblastoma, NB84	+++	0	++/+	+++
MUM1, MUM1p *	+++	+	++(+)	++(+)
Podoplanin. D2-40 **	+++	+	++(+)	++(+)
Hairy Cell, DBA.44 **	+++	0	++(+)	+++
Oct-2 (C20), poly *	+++	0	++(+)	+++
CD27, 137B4 **	+++	0	++(+)	+++
CEA, Col-1	+++	0	++(+)	+++
NSE, H14	+++	+(+)	++(+)	+++
CD117, YR145	+++	++(+)	++(+)	+++

Decalcification and CD279, NAT105







No decalcification Formic acid 16hrs EDTA 96hrs

Decalcification and CD303, 124B3.13







No decalcification Formic acid 16hrs EDTA 96hrs

Fixation time and decalcification in buffet formic acid (BFA)

Bcl2, clone124

	NBF 6 hrs	NBF 24 hrs	NBF 48 hrs
No decal			
+			
BFA 16 hrs			

Decalcification

- Most antigens don't survive decalcification in strong acid (e.g. Decal™)
- All tested antigens survive decalcification in EDTA and show no, or minimal reduction in staining intensity
- Only very few antigens don't survive decalcification in formic acid, but app. 10% show a slight reduction in staining intensity - learn!

Effects of Decalcification on Immunohistochemistry Comparing: Immunocal®, Formical2000®, and EDTA Stat®

Philip E. Ferguson, M.D.[1,2,3] & Yolanda Sanchez, MS-CRM[4]

[1]PathMD, LLC, [2]Doctors' Anatomic Pathology Services, [3]Saint Bernards Medical Center, and [4]Leica Biosystems

Antibodies:

CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD19, CD20, CD31, CD34, CD45, CD79a, CD138, Bcl-2, Bcl-6, Ki-67, AE1/AE3, BerEP4, CDX-2, CAM5.2, CK7, CK20, Desmin, E-Cadherin, MOC-31, S-100, Smooth Muscle Myosin-HC (SMM-HC), and CEA.



Conclusions: As expected, decalcification has negative effects on IHC staining. Weak acid decalcification reagents (Formical2000 and Immunocal) showed better performance characteristics compared to EDTA Stat*, (in contrast to Odense findings!) and nuclear transcription markers appear to be more sensitive to the effects of decalcification.

** The exact formulation of EDTA Stat solution is unknown*

Decalcification

Preanalytic variable	Published Guidelines and Recommendations	Literature-Based Recommendations
Decalcification	CLSI Interpret with caution - antigens could be lost!	Tissue should be fixed 24 hrs in NBF prior to decalcification. EDTA < Formic acid < Strong acid

International Journal of Laboratory Hematology
The Official journal of the International Society for Laboratory Hematology

REVIEW INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY

Int. Jnl. Lab. Hem. 2015, **37**, 431–449

ICSH guidelines for the standardization of bone marrow immunohistochemistry

E. E. TORLAKOVIC*, R. K. BRYNES†, E. HYJEK‡, S.-H. LEE§, H. KREIPE¶, M. KREMER**, R. MCKENNA††, Y. SADAHIRA‡‡, A. TZANKOV§§, M. REIS¶¶, A. PORWIT*,***, FOR THE INTERNATIONAL COUNCIL FOR STANDARDIZATION IN HAEMATOLOGY

Table 1. Recommended protocols for bone marrow (BM) fixation and decalcification

Turnaround time (TAT)*	Fixative	Fixation time	Decalcification	Decal time	Comments
Very short TAT	Acetic acid–zinc–formalin (AZF)	2–72 h†	Shandon™ TBD-1™ Decalcifier	30–40 min†	Whenever possible, longer fixation (within the range) is preferred
Intermediate TAT	AZF	Overnight	Gooding and Stewart's decalcification fluid (10% formic acid and 5% formaldehyde)‡	6 h	So-called 'Hammersmith Protocol'
Standard TAT	10% buffered formalin = 3.7% formaldehyde	8–72 h (overnight fixation is preferred)†	14% EDTA	16–24 h†	Preferred protocol for BM biopsy fixation and decalcification

*Consideration of agitation and warming to 37 °C of the decalcifying solutions are recommended for each protocol. Ultrasonic decalcification may also be employed. These methods were shown to significantly shorten TAT.
†The timing may vary based on ancillary use of stirrers, ultrasound energization, microwave or other heating methods, or their combination.
‡Although decalcifying fixative is not recommended to be used alone, decalcifying fixative can produce superior results when used after the BM biopsy was already properly fixed in AZF or formalin.

A Comparison of Immunohistochemical Stain Quality in Conventional and Rapid Microwave Processed Tissues

Lyska L. Emerson, MD,[1] Sheryl R. Tripp, MT(ASCP), QIHC(ASCP),[2] Bradley C. Baird, MS, MStat,[3] Lester J. Layfield, MD,[1] and L. Ralph Rohr, MD[1]

Am J Clin Pathol 2006;125:176-183

Energy Beam Sciences

Table 3
Microwave Processing Schedules

Short Microwave Schedule	Long Microwave Schedule
100% reagent-grade alcohol, 5 min, 67°C	100% reagent-grade alcohol, two 10-min cycles, 67°C
100% isopropanol, 5 min, 74°C	100% isopropanol, two 10-min cycles, 74°C
Paraffin, 5 min, 80°C (paraffin preheated to 75°C)	Paraffin, 10 min, 75°C (paraffin preheated in Lipshaw paraffin dispenser pot to 75°C and repeated for another 10 min, 80°C)
Total time, 15 min	Total time, 60 min

Table 2
Conventional Processing Schedules for Small and Large Specimens

Small Specimen Processing Times*	Large Specimen Processing Times*
Formalin, 60/40°C	Formalin, 60/40°C
Formalin, 60/40°C	Formalin, 60/40°C
70% alcohol, 20/40°C	70% alcohol, 45/40°C
95% alcohol, 30/40°C	95% alcohol, 45/40°C
95% alcohol, 30/40°C	95% alcohol, 60/40°C
100% alcohol, 30/40°C	100% alcohol, 45/40°C
100% alcohol, 30/40°C	100% alcohol, 45/40°C
100% alcohol, 30/40°C	100% alcohol, 60/40°C
Xylene, 30/40°C	Xylene, 60/40°C
Xylene, 30/40°C	Xylene, 60/40°C
Paraffin, 10/60°C	Paraffin, 30/60°C
Paraffin, 20/60°C	Paraffin, 30/60°C
Paraffin, 10/60°C	Paraffin, 30/60°C
Paraffin, 20/60°C	Paraffin, 30/60°C
Total time, 8 h*	Total time, 12 h*

* Times are given in minutes, followed by the processing temperature. Total times listed exceed the sums of the listed times for each schedule due to time required for reagent exchanges.

Table 4
Immunohistochemical Analysis

Antibody	Manufacturer	Pretreatment	Dilution/Time (min)*
AE1/3	Boehringer Mannheim, Indianapolis, IN	Protease 2, 8 min	1:2,800/32
C-NEU	Oncogene, Boston, MA	Microwave retrieval	1:1,600/32
CA 125	Signet, Dedham, MA	Microwave retrieval	1:200/32
Calcitonin	DAKO, Carpinteria, CA	None	1:500/10 (room temperature)
Calretinin	Zymed, San Francisco, CA	Microwave retrieval	1:160/32
CAM 5.2 (Cyto.8/18)	Novocastra, Newcastle upon Tyne, England	Protease 1, 2 min	1:40/32
CD1a	Immunotech, Marseille, France	Microwave retrieval	Prediluted/25
CD3	Novocastra	Pressure cooker retrieval, BORG buffer, pH 9.5 (Biocare Medical, Walnut Creek, CA)	1:100/32
CD15	Becton Dickinson, San Jose, CA	Pressure cooker retrieval, citrate buffer, pH 6.0	1:20/32 (with amplification kit)
CD20	DAKO	Microwave retrieval	1:2,000/32
CD30	DAKO	Pressure cooker retrieval, citrate buffer, pH 6.0	1:200/32 (with amplification kit)
CD31	DAKO	Microwave retrieval	1:40/32
CD34	BioSource, Camarillo, CA	Microwave retrieval	1:200/32
CD45	DAKO	Microwave retrieval	1:1,000/32
CD45RO	Zymed	Microwave retrieval	1:2,000/32
CD79a	DAKO	Pressure cooker retrieval, citrate buffer, pH 6.0	1:160/32
CD99 (O13)	Signet	None	1:200/32
CEA (polyclonal)	DAKO	None	1:800/32
Chromogranin	Novocastra	Microwave retrieval	1:100/32
CK5/6	Chemicon, Temecula, CA	Pressure cooker retrieval, citrate buffer, pH 6.0; protease 2, 2 min	1:160/32
CK7	DAKO	Microwave retrieval	1:400/32
CK20	DAKO	Microwave retrieval	1:200/32
Desmin	DAKO	Microwave retrieval	1:200/32
EMA	DAKO	Microwave retrieval	1:200/32
Estrogen receptor	Ventana Medical Systems, Tucson, AZ	Pressure cooker retrieval, citrate buffer, pH 6.0	Prediluted/32
FVIII	DAKO	Microwave retrieval	1:1,600/32
GFAP	DAKO	Microwave retrieval	1:400/32
HCG	DAKO	Microwave retrieval	1:3,000/10 (room temperature)
HPL	DAKO	Microwave retrieval	1:12,800/10 (room temperature)
HMB45	DAKO	Protease 2, 6 min	1:100/32
Inhibin	Serotec, Raleigh, NC	Pressure cooker retrieval, citrate buffer, pH 6.0	1:25/overnight (room temperature; with amplification kit)
Keratin903	Enzo, Farmingdale, NY	Microwave retrieval	1:40/32 (with amplification kit)
Melan A	DAKO	Pressure cooker retrieval, citrate buffer, pH 6.0	1:50/32 (with amplification kit)
Muramidase (lysozyme)	DAKO	Protease 2, 8 min	1:3,200/32
MSA	DAKO	None	1:100/32
PLAP	DAKO	Microwave retrieval	1:200/32
Progesterone receptor	Ventana Medical Systems	Pressure cooker retrieval, citrate buffer, pH 6.0	Prediluted/32
PAP	DAKO	Microwave retrieval	1:1,600/32
S-100	DAKO	Microwave retrieval	1:3,000/32
SMA	DAKO	None	1:200/32
Synaptophysin	DAKO	Microwave retrieval	1:200/32
Thyroglobulin	DAKO	Pressure cooker retrieval, citrate buffer, pH 6.0	1:500/32
Vimentin	DAKO	Microwave retrieval	1:300/32

CEA, carcinoembryonic antigen; CK, cytokeratin; EMA, epithelial membrane antigen; FVIII, factor VIII; GFAP, glial fibrillary acidic protein; HCG, human chorionic gonadotropin; HPL, human placental lactogen; MSA, muscle-specific actin; PAP, prostatic acid phosphatase; PLAP, placental alkaline phosphatase; SMA, smooth muscle actin.
* Unless otherwise specified.

A Comparison of Immunohistochemical Stain Quality in Conventional and Rapid Microwave Processed Tissues

Lyska L. Emerson, MD,[1] Sheryl R. Tripp, MT(ASCP), QIHC(ASCP),[2]
Bradley C. Baird, MS, MStat,[3] Lester J. Layfield, MD,[1] and L. Ralph Rohr, MD[1]



Figure 1 Percentages of cases differing in extent of staining.



Figure 2 Percentages of cases differing in intensity of staining.

Implementation of a Microwave-assisted Tissue-processing System and an Automated Embedding System for Breast Needle Core Biopsy Samples: Morphology, Immunohistochemistry, and FISH Evaluation

Enrico Pegolo, MD, Maura Pandolfi, BSc, and Carla Di Loreto, MD

(*Appl Immunohistochem Mol Morphol* 2012;00:000–000)

Material: *233 consecutive needle core breast biopsies.*
The fixation time was strictly standardized, ranging from 18 to 24 hours.
After fixation, half of the core specimens from each case were randomly assigned to the conventional processing system (Leica ASP 300S 16-hrs program) and the other half to the MW-assisted tissue-processing system Sakura Tissue-Tek Xpress 120 (1-hr program).

TABLE 2. Immunohistochemical Analysis

Antibodies	Clone, Species	Manufacturer	Pretreatment	Dilution/Time
CK 5/6	D5/16B4, mouse	Dako	Tris/EDTA buffer (pH 9) at 97°C for 15 min	1:50/30 min
CK 19	RCK108, mouse	Dako	Citrate buffer (pH 6.1) at 97°C for 20 min	1:50/20 min
E-cadherin	NCH-38, mouse	Dako	Citrate buffer (pH 6.1) at 97°C for 20 min	1:100/20 min
p63	4A4, mouse	Dako	Citrate buffer (pH 6.1) at 97°C for 20 min	1:100/20 min
SMA	1A4, mouse	Dako	Tris/EDTA buffer (pH 9) at 97°C for 15 min	1:200/20 min
ER	SP1, rabbit	Aczonpharma (Bologna, Italy)	Citrate buffer (pH 6.1) at 97°C for 20 min	1:200/40 min
PR	PgR 636, mouse	Dako	Citrate buffer (pH 6.1) at 97°C for 20 min	1:100/40 min
Ki-67	Mib-1, mouse	Dako	Citrate buffer (pH 6.1) at 97°C for 20 min	1:50/20 min
HercepTest	Polyclonal, rabbit	Dako	Dako Epitope Retrieval Solution	Predil/30 min

CK indicates cytokeratin; ER, estrogen receptor; PR, progesterone receptor; Predil, prediluted; SMA, smooth muscle actin.

Implementation of a Microwave-assisted Tissue-processing System and an Automated Embedding System for Breast Needle Core Biopsy Samples: Morphology, Immunohistochemistry, and FISH Evaluation

Enrico Pegolo, MD, Maura Pandolfi, BSc, and Carla Di Loreto, MD

(*Appl Immunohistochem Mol Morphol* 2012;00:000–000)

TABLE 3. Estrogen Receptor Status in the Conventionally Processed and in the Matched MW-assisted Processed NCBs of Breast Carcinomas

	ER Status (Conventional)		
ER Status (MW)	**Positive**	**Negative**	**Total**
Positive	62	0	62
Negative	0	16	16
Total	62	16	78

Cohen κ test = 1.

ER indicates estrogen receptor; MW, microwave-assisted processing system; NCB, needle core biopsy.



FIGURE 2. Needle core biopsy: invasive ductal carcinoma. Immunohistochemical reaction for estrogen receptor in the nuclei of tumor cells. The reaction is the same in the specimens prepared using the conventional processing method (A) and the microwave-assisted processing method (B) (A and B, immunoperoxydase for estrogen receptor, hematoxylin counterstain, original magnification ×200). full color online

Implementation of a Microwave-assisted Tissue-processing System and an Automated Embedding System for Breast Needle Core Biopsy Samples: Morphology, Immunohistochemistry, and FISH Evaluation

Enrico Pegolo, MD, Maura Pandolfi, BSc, and Carla Di Loreto, MD

(*Appl Immunohistochem Mol Morphol* 2012;00:000–000)

TABLE 6. HER2 Immunohistochemical Results in the Conventionally Processed and in the Matched MW-assisted Processed NCBs of Breast Carcinomas

	HER2 IHC (Conventional)			
HER2 IHC (MW)	**Negative**	**Equivocal**	**Positive**	**Total**
Negative	50	0	0	50
Equivocal	2	11	0	13
Positive	0	0	8	8
Total	52	11	8	71

Cohen κ test = 0.93. $P = 0.88$, χ^2 test.

IHC indicate immunohistochemistry; MW, microwave-assisted processing system; NCB, needle core biopsy.

The quality of H&E and immunohistochemical tissue sections provided by the new system is comparable to that obtained after the conventional processing method; this system also reduces the turnaround time for surgical pathology reports. Moreover, this is the first study that validates the assessment of the main prognostic and predictive biomarkers in breast NCBs processed by a MW-assisted system and automatically embedded.



FIGURE 5. Needle core biopsy: invasive ductal carcinoma. Immunohistochemical reaction for HER2 (HercepTest) in the cell membranes of tumor cells. The same strong complete membrane staining (score 3+) is observed in the specimens prepared using the conventional processing method (A) and the microwave-assisted processing method (B) (A and B, HercepTest, original magnification ×200). full color online

Processing

Preanalytic variable	Published Guidelines and Recommendations ASCO/CAP | CLSI	Literature-Based Recommendations
Dehydration	1.25 - 15 hrs	10 hrs
Type of paraffin	Paraffin (55°C-58°C)	Paraffin (45°C)
Time in paraffin	0.5 - 4.5 hrs	1 - 2 hrs or 8 hrs

Engel KB, Moore HM. Arch Pathol Lab Med. 2011;135:537–543

Paraffin sectioning

- Type of blade and frequency of replacement
- Frequency of servicing and wax replacement
- Temperature of block during sectioning
- Slide pretreatment
- Water bath conditions, if used
- Chemical adhesives, if used
- Temperature and duration of slide drying

Immunocytochemistry 2008; Volume 6 Issue 3

TECHNICAL ARTICLE

EXCESSIVE SECTION DRYING OF BREAST CANCER TISSUE PRIOR TO DEPARAFFINISATION AND ANTIGEN RETRIEVAL CAUSES A LOSS IN HER2-IMMUNO-REACTIVITY

Bent Lundgaard Hansen, Henrik Winther and Kristian Moller

Dako A/S, DK-2600, Glostrup, Denmark

Antibodies:
a. HercepTest
b. Clone 4B5
c. Clone CB11



60°C/60’



80°C/16 hrs

“Procedure for drying of tissue prior to deparaffinization: The drying temperature should be 60°C for a maximum of one hour, 37 °C for a maximum of 24 hours, or ambient temperature for 24 hours or longer”.



60°C/60’



60°C/16 hrs

Drying of sections - HER2, 4B5



60 min at 60°C



16 hrs at 80°C

Drying of sections - ER, SP1



60 min at 60°C



16 hrs at 80°C

Drying of sections (Baking)

Preanalytic variable	Published Guidelines and Recommendations ASCO/CAP | CLSI	Literature-Based Recommendations
Drying of sections	24 hrs at RT or 1 hr at 50°C - 60°C	24 hrs at RT or overnight at 37°C

Engel KB, Moore HM. Arch Pathol Lab Med. 2011;135:537–543

Storage

- Temperature and duration of paraffin block storage

- Temperature, duration, and manipulation of slide-mounted tissue sections

Modern Pathology (2004) 17, 1414–1420

www.modernpathology.org

Influence of slide aging on results of translational research studies using immunohistochemistry

Martina Mirlacher, Marlis Kasper, Martina Storz, Yvonne Knecht, Ursula Dürmüller, Ronald Simon, Michael J Mihatsch and Guido Sauter



Fresh sections (F) vs. sections stored at 4°C for 6 months (O)



Figure 2 Influence of slide aging on the fraction of positive cases. For each antibody, the frequency of positive cases is shown as separate bars for old (O) and fresh (F) sections.



HER2 (F)



ER (F)



HER2 (O)



ER (O)

Modern Pathology (2004) 17, 1414–1420

www.modernpathology.org

Influence of slide aging on results of translational research studies using immunohistochemistry

Martina Mirlacher, Marlis Kasper, Martina Storz, Yvonne Knecht, Ursula Dürmüller, Ronald Simon, Michael J Mihatsch and Guido Sauter

Fresh sections vs. sections stored at 4°C for 6 months





de aging on survival analyses. The
tcome of survival analyses performed
h and old sections. (a) ER staining on
ER staining on old sections. (c) PR
tions. (d) PR staining on old sections.
y cut sections. (f) HER2 staining on old

"The results confirm that slide aging has a great influence on the intensity of IHC staining in individual cases, but they also suggest that many clinicopathological associations can be detected if suboptimally processed sections are used for IHC".

Influence of Storage Temperature and High-Temperature Antigen Retrieval Buffers on Results of Immunohistochemical Staining in Sections Stored for Long Periods

Applied Immunohistochemistry *6(4): 209–213, 1998*

Dorthe A. Grabau, M.D., Ph.D., Ole Nielsen, H.T., Steinbjørn Hansen, M.D., Mette M. Nielsen, M.D., Anne-Vibeke Lænkholm, M.D., Ann Knoop, M.D., and Per Pfeiffer, M.D., Ph.D.

Estrogen Receptor, 1D5

Storage at -80°C gave superior results

NordiQC



Factors Influencing the Degradation of Archival Formalin-Fixed Paraffin-Embedded Tissue Sections

Ran Xie, Joon-Yong Chung, Kris Ylaya, Reginald L. Williams, Natalie Guerrero, Nathan Nakatsuka, Cortessia Badie, and Stephen M. Hewitt

Tissue Array Research Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

(J Histochem Cytochem 59:356–365, 2011)

Water?

Aquaporin 1 (AQP1)

Factors Influencing the Degradation of Archival Formalin-Fixed Paraffin-Embedded Tissue Sections

Ran Xie, Joon-Yong Chung, Kris Ylaya, Reginald L. Williams, Natalie Guerrero, Nathan Nakatsuka, Cortessia Badie, and Stephen M. Hewitt
Tissue Array Research Program, Laboratory of Pathology, Center for Cancer Research. National Cancer Institute. National Institutes of Health. Bethesda, Maryland.

(J Histochem Cytochem 59:356–365, 2011)

Slide storage 2-weeks

Slide storage 0



Storage 3 months

Factors Influencing the Degradation of Archival Formalin-Fixed Paraffin-Embedded Tissue Sections

Ran Xie, Joon-Yong Chung, Kris Ylaya, Reginald L. Williams, Natalie Guerrero, Nathan Nakatsuka, Cortessia Badie, and Stephen M. Hewitt
Tissue Array Research Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

(J Histochem Cytochem 59:356–365, 2011)



"This study revealed that inadequate tissue processing, resulting in retention of endogenous water in tissue sections, results in antigen degradation. Exposure to high humidity during storage results in significant protein degradation and reduced immunoreactivity, and the effects of storage humidity are temperature dependent".



Loss of antigenicity with tissue age in breast cancer

Susan E Combs[1], Gang Han[1], Nikita Mani[1], Susan Beruti[2], Michael Nerenberg[3] and David L Rimm[1]

Laboratory Investigation (2016) 96, 264–269



Figure 1 A consort diagram showing the cohorts from which the tissues were derived and the date ranges for each followed by the number of cases analyzed for each biomarker. IHC, immunohistochemistry; TMA, tissue microarray.

The average signal decreased with preservation time for all biomarkers measured. For **ER** and **HER2**, there was an average of 10% signal loss after 9.9 years and 8.5 years, respectively, compared with the most recent tissue. Detection of **Ki67** expression was lost more rapidly, with 10% signal loss in just 4.5 years. Overall, these results demonstrate the need for adjustment of tissue age when studying FFPE biospecimens. The rate of antigenicity loss is biomarker specific and should be considered as an important variable for studies using archived tissues.



Figure 2 The distribution of scores for each biomarker as a function of tissue age after omitting the fraction of expected negative cases. (**a**) ER, (**b**) HER2, (**c**) Ki67 and (**d**) cytokeratin. The fraction of positive cases is shown by percentage beneath the biomarker in the title. The regression value and *P*-value are presented in the insets. Au, arbitrary unit.

Loss of antigenicity with tissue age in breast cancer

Susan E Combs[1], Gang Han[1], Nikita Mani[1], Susan Beruti[2], Michael Nerenberg[3] and David L Rimm[1]

Laboratory Investigation (2016) 96, 264–269



Figure 1 A consort diagram showing the cohorts from which the tissues were derived and the date ranges for each followed by the number of cases analyzed for each biomarker. IHC, immunohistochemistry; TMA, tissue microarray.

The average signal decreased with preservation time for all biomarkers measured. For **ER** and **HER2**, there was an average of 10% signal loss after 9.9 years and 8.5 years, respectively, compared with the most recent tissue. Detection of **Ki67** expression was lost more rapidly, with 10% signal loss in just 4.5 years. Overall, these results demonstrate the need for adjustment of tissue age when studying FFPE biospecimens. The rate of antigenicity loss is biomarker specific and should be considered as an important variable for studies using archived tissues.



Figure 3 Random effects model curves for each biomarker showing the loss of antigenicity of each biomarker as a function of tissue age with best fit equation of loss inset with *P*-value. (**a**) ER, (**b**) HER2, (**c**) Ki67 and (**d**) cytokeratin.

Storage of specimen

Preanalytic variable	Published Guidelines and Recommendations ASCO/CAP | CLSI	Literature-Based Recommendations
Storage of paraffin blocks	Indefinitely *	< 25 years
Storage of sections (slide)	7 days or < 6 weeks	< 6 days

Engel KB, Moore HM. Arch Pathol Lab Med. 2011;135:537–543

Days	20°C
Weeks	4°C
Months	-20°C
Years	-80°C

* new data indicates up to 10% loss in 5 years

Effects of Preanalytical Variables on the Detection of Proteins by Immunohistochemistry in Formalin-Fixed, Paraffin-Embedded Tissue

Kelly B. Engel, PhD; Helen M. Moore, PhD

Arch Pathol Lab Med—Vol 135, May 2011

Table 1. Potential Sources of Preanalytic Variation During Specimen Fixation and Processing

- Prefixation
  - Duration and delay of temperature
  - Specimen size
  - Specimen manipulation (pathology ink)
- Fixative
  - Formula
  - Concentration
  - pH
  - Age of reagent
  - Preparation source
- Fixation
  - Tissue to fixative volume ratio
  - Method (immersion, injection, and sonication or microwave acceleration)
  - Conditions of primary and secondary fixation
    - Movement
    - Light exposure
    - Primary container
    - No. and position of cofixed specimens
- Postfixation
  - Washing conditions and duration
  - Storage reagent and duration
- Processing
  - Type of processor, frequency of servicing and reagent replacement
  - Tissue to reagent volume ratio
  - No. and position of coprocessed specimens
- Dehydration and clearing
  - Reagent
  - Temperature
  - No. of changes
  - Duration (total and change-specific)
- Paraffin impregnation
  - Type and melting point of wax
  - No. of changes
  - Duration (total and change-specific)
  - Method (immersion and sonication or microwave acceleration)
- Paraffin sectioning
  - Type of blade and frequency of replacement
  - Frequency of servicing and wax replacement
  - Temperature of block during sectioning
  - Slide pretreatment
  - Water bath conditions, if used
  - Chemical adhesives, if used
  - Temperature and duration of slide drying
- Storage
  - Temperature and duration of paraffin block storage
  - Temperature, duration, and manipulation of slide-mounted tissue sections

Decalcification:
Type, Time, Temperature

A tissue quality index: an intrinsic control for measurement of effects of preanalytical variables on FFPE tissue

Veronique M Neumeister[1], Fabio Parisi[1], Allison M England[1], Summar Siddiqui[1], Valsamo Anagnostou[1], Elizabeth Zarrella[1], Maria Vassilakopolou[1], Yalai Bai[1], Sasha Saylor[1], Anna Sapino[2], Yuval Kluger[1,2], David G Hicks[3], Gianni Bussolati[2], Stephanie Kwei[4] and David L Rimm[1]

Laboratory Investigation (2014) 94, 467–474

- Aim: Developing a quantitative intrinsic control that can measure the degree of degradation of any FFPE sample.
- If we cannot control pre- analytical variables can we quantify the damage or tissue degradation caused by them?
- Can we disqualify specimens for Companion dx testing?

TQI: Tissue Quality Index

Table 1 Antibodies tested for the TQI

Symbol	Description	Antibody Clone/Isotype	Supplier
Markers of Cold Ischaemia			
ACTB	Beta-Actin	13E5/IgG	Cell Signaling Technology
TUBB	Beta-Tubulin	pF3/IgG	Cell Signaling Technology
GAPDH	Glyceraldehyde-3-phosphate dehydrogenase	14C10/IgG	Cell Signaling Technology
HIST4	Histone 4	L64C1	Cell Signaling Technology
HIST3	Histone 3	96C10/IgG1, kappa	Cell Signaling Technology
LMNA/C	Lamin A/C	Polyclonal	Cell Signaling Technology
LDHA	Lactat Dehydrogenase	IgG, C4B5	Cell Signaling Technology
ERalpha	Estrogen Receptor alpha	SP1/IgG	Thermo Scientific
CK	Cytokeratin	AE1/AE3/IgG1	DAKO
CK	Cytokeratin	Polyclonal	DAKO
ERK1/2	P44/42MAPK (Erk1/2)	137F5, IgG	Cell Signaling Technology
p53	Anti-Human p53 protein	IgG2b. DO-7	DAKO
Markers of Hypoxia			
CCND1	Cyclin D1	IgG/SP4	Thermo Fisher Fremont
Caspase	Cleaved Caspase 3 (Asp175)	Polyclonal	Cell Signaling Technology
HIF1	Hypoxia Inducible Factor 1	Polyclonal	Novus Biological
AKAP13	A-kinase anchoring protein 13	IgG2a/ZX-18	
CDC42		IgG3/B-8	
CCNB1	Cyclin B1	GNS-11/IgG2	
HIF-2alpha	Hypoxia inducible factor-2α	ep190b/IgG1	
CA9	Carbonic Anhydrase IX	Polyclonal(aa581-59	
Markers of phosphorylated proteins			
pAKT 473	phospho-Akt (ser473)	D9E/IgG	Cell Signaling Technology
ERK1/2	Phospho-p44/43MAPK (Erk1/2) (Thr292/Tyr204)	IgG	Cell Signaling Technology
pER	Phospho-Estrogen Receptor alpha (Ser118)	16J4/IgG2b	Cell Signaling Technology
Anti-Phosphotyrosine	4G10 Anti-Phosphotyrosine	IgG2b	Millipore
Anti-Phosphotyrosine		p-Tyr-100	Cell Signaling Technology
pHSP27 (pS78)	Phosphorylated Heat Shock Protein 27	Y175	Epitomics
pHer2 (Tyr1248)	Phospho-Her2/ErbB2 (Tyr1248)	PN2A	Thermo Scientific
Phospho-Stat3 (Tyr705)	Phospho-Stat3 (Tyr705)	D3A7/IgG	Cell Signaling Technology
p-S6 Ribosomal Protein (Ser235/236)	Phospho-S6 Ribosomal Protein (Ser235/236)	D52.2.2E/IgG	Cell Signaling Technology
Phospho-Jak2 (Tyr1007/1008)	Phospho-Jak2 (Tyr1007/1008)	Polyclonal	Cell Signaling Technology
Phospho-Met (Tyr1234/1235)	Phospho-Met (Tyr1234/1235)	IgG	Cell Signaling Technology
Phospho-Sapk/Jnk	Phospho-Sapk/Jnk	IgG	Cell Signaling Technology
Phospho mTor (Ser2448)	Phospho mTor (Ser2448)	49F9/IgG	Cell Signaling Technology
Markers of posttranslational modification			
Sumo1	small ubiquitin related modifier 1	Y299/IgG	Abcam
Acetylated-Lysine	Proteins posttranslat. Modified by acetylation	Polyclonal, purified	Cell Signaling Technology
NEDD8	Neural precursor cell-expr. devel. Downreg. protein9	IgG, 19E3	Cell Signaling Technology

TQI: Tissue Quality Index



Figure 1 (**a**) The performance of six marker combinations on the testing and validation subgroup of the time to fixation breast cancer series as measured by receiver-operator characteristic (ROC) curves and area under the curve (AUC) values. The tissue quality index (TQI) was then calculated on the complete time to fixation breast cancer series. (**b**) TQI values of cytokeratin:pHSP27 and (**c**) ERK1/2:pHSP27 in relationship with increasing cold ischemic time.

“The poor man’s TQI”

“Damage Controls”

- **Fixation delay/Cold ischemia**
  - CD138, B-A38
- **Poor/short fixation in NBF**
  - MLH1, ES05
  - PMS2, EPR3947
  - BCL6, LN22
  - BCL2, 124
- **Electrosurgery**
  - CK, CAM5.2

CD138: Simple marker of fixation delay

Odense data



Liver: No Fix delay



Liver 16 hrs delay



Liver 48 hrs delay

CD138 (B-A38): Simple marker of fixation delay

Odense data



Plasmacytoma

CK, CAM5.2 simple marker of electrosurgery



HE

RCC



CK, CAM5.2

Markers of poor/short NBF fixation



BCL6, LN22

Tonsil



PMS2, EPR3947

National Cancer Institute | U.S. National Institutes of Health | www.cancer.gov

BBRB Biorepositories and Biospecimen Research Branch

Launch NCI Best Practices | Launch caHUB

Sign Up For Updates | Search

About BBRB | About NCI Best Practices | Biospecimen Research Network | caHUB | News and Events | Resources

Biospecimen Research Database



- Home
- Search
  - Quick Search
  - Simple Search
  - Advanced Search
  - Experimental Factor Search
- Suggest New Paper
- Curator Login

Welcome to the Biospecimen Research Database

The Biospecimen Research Database (BRD) is a free and publicly accessible database that contains peer-reviewed literature pertinent to the field of human biospecimen science. The database is updated periodically with both recent and historical publications and may serve as a vehicle for literature review, evaluation of "in use" biospecimen handling protocols, development of new protocols, and identification of analytes that are susceptible or impervious to handling variability.

A login is not required to enter or search the BRD, simply hit "Search " to begin.

Users may suggest articles for curation through the new "Suggest a new paper " feature, located on the left navigation bar. Article suggestions may also be submitted to biospecimens@mail.nih.gov. We welcome your feedback.

The BRD (http://brd.nci.nih.gov/) is an initiative of the BRN program. BRD paper entries include primary research or review articles that have been identified, reviewed, and curated by a Ph.D. level scientist. For each paper contained within the BRD (1) relevant parameters have been annotated, including the biospecimen investigated (tissue/cell type, patient diagnosis), the preservation method employed, the analyte of interest, and the technology platform applied; (2) relevant results have been summarized in free-text fields; and (3) variables encountered during the lifecycle of a biospecimen (e.g. ischemia time, fixation parameters, storage conditions) have been captured by experimental factors.

https://brd.nci.nih.gov/BRN/brnHome.seam

Thank you for your attention!